How Eplerenone Affects Renin and Aldosterone
Eplerenone causes sustained increases in both plasma renin activity and serum aldosterone levels by blocking the mineralocorticoid receptor and interrupting the negative feedback loop that aldosterone normally exerts on renin secretion. 1
Mechanism of Action
Eplerenone binds to the mineralocorticoid receptor and blocks aldosterone binding, which is a key component of the renin-angiotensin-aldosterone system (RAAS). When eplerenone blocks the mineralocorticoid receptor, it disrupts the normal negative regulatory feedback that aldosterone exerts on renin secretion 1. This blockade triggers a compensatory physiologic response:
Expected Hormonal Changes:
- Plasma renin activity increases - The body attempts to overcome the receptor blockade by increasing renin production
- Serum aldosterone levels increase - Aldosterone production rises in response to elevated renin activity
- These elevated levels do not overcome eplerenone's effects - Despite the compensatory increases in circulating renin and aldosterone, the mineralocorticoid receptor blockade remains effective 1
Clinical Evidence
Research confirms these physiologic changes occur consistently:
- In HIV-infected patients treated with eplerenone 50 mg daily, both plasma renin activity and aldosterone levels increased significantly, demonstrating the expected physiology of mineralocorticoid receptor antagonism 2
- In hypothyroid rats, eplerenone caused significant increases in renin (from 184.09 pg/ml to 603.31 pg/ml) and angiotensin I (from 178.66 pg/ml to 250.88 pg/ml) 3
- In hyperthyroid rats, eplerenone significantly increased aldosterone (from 364.23 pg/ml to 497.02 pg/ml) and angiotensin I 3
- In hypertensive patients, increases in serum aldosterone were dose-related but not correlated with blood pressure reductions, confirming that the therapeutic effects occur despite elevated aldosterone levels 4
Important Clinical Context:
The increases in renin and aldosterone are markers of effective mineralocorticoid receptor blockade, not treatment failure. This is a predictable pharmacodynamic response that confirms the drug is working as intended 1, 2.
Monitoring Implications
When initiating eplerenone therapy:
- Measurement of renin (as a marker of mineralocorticoid receptor blockade) may assist in dose titration for achieving blood pressure control and normokalemia 5
- The goal is clinical response (blood pressure control, potassium normalization), not suppression of renin or aldosterone levels
- Most patients achieve renin de-suppression with spironolactone-equivalent doses between 50-100 mg/day 5
Critical caveat: In oligo-anuric hemodialysis patients, eplerenone reduced blood pressure without affecting plasma aldosterone concentrations or plasma renin activity, suggesting the mechanism may differ in patients without functional kidneys 6. However, in patients with normal renal function, the expected pattern is sustained elevation of both renin and aldosterone.